Skip to content

Clinical study of deep brain stimulation in the treatment of Meige syndrome

Clinical study of deep brain stimulation in the treatment of Meige syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032852
Enrollment
Unknown
Registered
2020-05-13
Start date
2020-05-25
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meige syndrome

Interventions

STN DBS group:Accept bilateral STN DBS
GPi DBS group:Accept bilateral GPi DBS

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as primary Meige syndrome; 2. Patients who fail to control the symptoms and seriously affect the quality of life after the treatment of oral drugs and botulinum toxin; 3. Patients in good health except for dystonia; 4. Patients with normal screening results by MMSE; 5. The subjects or their families can fully understand the treatment and sign the informed consent; 6. The patients with good compliance can cooperate with the patients who complete the postoperative follow-up requirements.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal changes of basal ganglia on imaging; 2. Patients with serious progressive nervous system, cardiovascular system, respiratory system or digestive system diseases; patients with unstable mental state; 3. Patients with contraindications to surgery or anesthesia, such as taking anticoagulant and antiplatelet drugs for a long time; 4. Women who plan to be pregnant, or are in pregnancy and lactation; 5. Patients who have or need other implantable devices, such as pacemakers, defibrillators, cochlear implants and chiropractic root stimulators; 6. Patients who need 3.0T MRI for many times in the future clinical trials due to their own reasons; 7. Patients who have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Burke- fahn-marsden Dystonia Rating scale (BFMDRS);

Secondary

MeasureTime frame
Mini-Mental State Examination, MMSE;Montreal Cognitive Assessment, MoCA;Hamilton Dpression Scale, HAMD;Hamilton Anxiety Scale, HAMA;Health-related quality of life (QOL), SF-36;

Countries

China

Contacts

Public ContactWei Wang

West China Hospital, Sichuan University

wcnsww@163.com+86 18980601521

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026